Copalia (Amlodipine 5 mg / Valsartan 80 mg)

What Is Copalia and What Is It Used For?

Copalia is a fixed-dose combination antihypertensive medication containing amlodipine 5 mg (a calcium channel blocker) and valsartan 80 mg (an angiotensin II receptor blocker). It is prescribed for the treatment of essential hypertension in adults when blood pressure is not adequately controlled by either component alone.

High blood pressure (hypertension) is one of the most significant modifiable risk factors for cardiovascular disease worldwide. According to the World Health Organization (WHO), approximately 1.28 billion adults aged 30–79 years have hypertension globally, with nearly half unaware of their condition. Uncontrolled hypertension substantially increases the risk of heart attack, stroke, heart failure, kidney disease, and peripheral vascular disease. Effective blood pressure management is therefore a cornerstone of cardiovascular disease prevention.

Copalia addresses this challenge by combining two well-established antihypertensive agents with complementary mechanisms of action. Amlodipine, a dihydropyridine calcium channel blocker (CCB), works by inhibiting the influx of calcium ions through L-type calcium channels in vascular smooth muscle cells. This results in relaxation of the arterial smooth muscle, leading to vasodilation and a reduction in peripheral vascular resistance. Amlodipine has a long half-life of approximately 30–50 hours, providing consistent 24-hour blood pressure control with once-daily dosing.

Valsartan, an angiotensin II receptor blocker (ARB), selectively blocks the binding of angiotensin II to the AT1 receptor. Angiotensin II is a potent vasoconstrictor that also stimulates aldosterone secretion, promoting sodium and water retention. By blocking these effects, valsartan reduces vasoconstriction, decreases aldosterone-mediated fluid retention, and consequently lowers blood pressure. Valsartan has the additional benefit of providing renal protective effects, which is particularly important in patients with diabetes or chronic kidney disease.

The rationale for combining these two agents is based on robust clinical evidence. The landmark VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial and multiple subsequent studies have demonstrated that combination therapy achieves target blood pressure in a significantly higher proportion of patients compared to monotherapy. The European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) 2023 guidelines recommend initial combination therapy for most patients with grade 2 or higher hypertension (systolic blood pressure ≥160 mmHg or diastolic ≥100 mmHg), and for patients with grade 1 hypertension at high cardiovascular risk.

What Should You Know Before Taking Copalia?

Before starting Copalia, your doctor must know about all your medical conditions, allergies, and current medications. Copalia is contraindicated in pregnancy, severe liver disease, and in combination with aliskiren in patients with diabetes or renal impairment. Kidney function and electrolytes should be monitored regularly.

Contraindications

Copalia must not be used in certain situations due to the risk of serious adverse effects. Understanding these contraindications is essential for safe prescribing and patient safety. Your healthcare provider will carefully evaluate your medical history before initiating treatment.

• Pregnancy: Copalia is contraindicated throughout pregnancy. Valsartan, as an angiotensin II receptor blocker, can cause injury and death to the developing fetus when used during the second and third trimesters. Effects include fetal hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. If pregnancy is detected, discontinue Copalia as soon as possible.
• Hypersensitivity: Do not take Copalia if you are allergic to amlodipine, valsartan, other dihydropyridine derivatives, or any of the excipients listed in the product information.
• Severe hepatic impairment: Copalia is contraindicated in patients with severe liver disease, biliary cirrhosis, or cholestasis, as valsartan is primarily eliminated by biliary excretion and amlodipine is extensively metabolized by the liver.
• Concomitant use with aliskiren: The combination of Copalia with aliskiren is contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR <60 mL/min/1.73 m²) due to the increased risk of hyperkalemia, hypotension, and renal dysfunction.
• Severe aortic stenosis: Amlodipine should be used with extreme caution in patients with severe aortic stenosis, as the vasodilatory effect may lead to dangerously low blood pressure in this population.

Warnings and Precautions

Several clinical situations require careful consideration and potentially enhanced monitoring when using Copalia. Discuss the following conditions with your doctor before starting treatment:

• Renal artery stenosis: In patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney, ARBs including valsartan may increase blood urea nitrogen and serum creatinine. Close monitoring of renal function is recommended in these patients.
• Volume or sodium depletion: Patients who are volume-depleted (e.g., from diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting) may experience symptomatic hypotension when starting Copalia. Volume status should be corrected before initiating therapy, or a lower starting dose should be considered.
• Heart failure: In patients with heart failure, CCBs like amlodipine should be used cautiously. Although amlodipine has been shown to be safe in patients with stable heart failure (PRAISE study), worsening heart failure and pulmonary edema have been reported with calcium channel blockers in general.
• Hyperkalemia: Valsartan can increase serum potassium levels, particularly in patients with renal impairment, diabetes mellitus, or those taking potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium. Regular monitoring of serum potassium is advised.
• Hepatic impairment: Patients with mild-to-moderate hepatic impairment without cholestasis may require dose adjustments. The bioavailability of valsartan is approximately doubled in patients with mild-to-moderate liver disease.

Your doctor may order regular blood tests to monitor kidney function (creatinine, eGFR), electrolytes (particularly potassium and sodium), and liver function during treatment with Copalia. These tests are especially important during the first few weeks of treatment, after dose adjustments, and in patients with pre-existing renal or hepatic conditions.

Pregnancy and Breastfeeding

Copalia is strictly contraindicated during pregnancy. Drugs that act directly on the renin-angiotensin system (RAS), including valsartan, can cause injury and death to the developing fetus. When pregnancy is detected, Copalia should be discontinued as soon as possible. Patients who become pregnant while taking Copalia should be informed of the potential hazard to the fetus and should be switched to an alternative antihypertensive medication that is considered safe during pregnancy, such as methyldopa, labetalol, or nifedipine.

There is limited data on the use of amlodipine and valsartan during breastfeeding. Both amlodipine and valsartan are excreted in human breast milk in low concentrations. Due to the potential for adverse effects in the nursing infant, a decision must be made whether to discontinue breastfeeding or discontinue Copalia, taking into account the importance of the medication for the mother. The European Medicines Agency (EMA) recommends that Copalia should not be used during breastfeeding, and alternative treatments with a better-established safety profile should be preferred.

Women of childbearing potential should use effective contraception during treatment with Copalia. Pre-treatment pregnancy testing is recommended, and patients should be counseled about the teratogenic risks. If planning a pregnancy, Copalia should be switched to an alternative antihypertensive before conception whenever possible.

How Does Copalia Interact with Other Drugs?

Copalia can interact with several other medications, including ACE inhibitors, aliskiren, potassium-sparing diuretics, NSAIDs, lithium, and CYP3A4 inhibitors. These interactions may increase the risk of hypotension, hyperkalemia, kidney injury, or altered drug levels. Always inform your doctor about all medications you are taking.

Drug interactions with Copalia arise from the pharmacological properties of both its components. Valsartan interacts primarily through effects on the renin-angiotensin-aldosterone system (RAAS) and renal function, while amlodipine interactions are largely related to its metabolism via cytochrome P450 3A4 (CYP3A4) enzymes and its vasodilatory effects. Understanding these interactions is critical for safe prescribing and avoidance of serious adverse events.

Dual blockade of the RAAS through the combination of Copalia with ACE inhibitors or aliskiren is generally not recommended. The ONTARGET trial demonstrated that combining an ACE inhibitor with an ARB provided no additional cardiovascular benefit but significantly increased the risk of hypotension, syncope, hyperkalemia, and renal dysfunction compared with either agent alone. The VA NEPHRON-D trial confirmed these findings in patients with diabetic nephropathy.

NSAIDs (nonsteroidal anti-inflammatory drugs), including selective COX-2 inhibitors, can attenuate the antihypertensive effect of valsartan by inhibiting renal prostaglandin synthesis. This is a clinically relevant interaction, as many patients with hypertension also use NSAIDs for pain management. Additionally, the combination of NSAIDs with ARBs may further impair renal function and increase the risk of acute kidney injury, particularly in patients who are already volume-depleted or have pre-existing renal impairment.

Major Interactions

Additional Considerations

Grapefruit juice is a known inhibitor of CYP3A4 and intestinal P-glycoprotein. While the clinical significance of the interaction between grapefruit juice and amlodipine is generally considered modest, excessive consumption may increase amlodipine blood levels and potentially enhance its blood pressure-lowering effect. Patients should be advised to consume grapefruit products in moderation.

Alcohol consumption can potentiate the vasodilatory effects of amlodipine, leading to an additional decrease in blood pressure. Patients should be counseled to limit alcohol intake and to be aware of symptoms of hypotension (dizziness, lightheadedness, fainting) when combining alcohol with Copalia.

What Is the Correct Dosage of Copalia?

The standard dose of Copalia is one tablet (amlodipine 5 mg / valsartan 80 mg) taken once daily, with or without food. Your doctor may adjust the dose based on your blood pressure response. The maximum recommended dose of the individual components is amlodipine 10 mg and valsartan 320 mg daily.

Copalia should be taken at approximately the same time each day to maintain consistent blood pressure control. The tablet should be swallowed whole with a glass of water. It can be taken with or without food, as food does not significantly affect the absorption of either active ingredient. Consistent daily use is essential, as the full antihypertensive effect typically develops over 2–4 weeks.

Adults

Elderly Patients

Patients with Renal Impairment

Patients with Hepatic Impairment

Missed Dose

If you miss a dose of Copalia, take it as soon as you remember on the same day. If it is already close to the time of your next dose, skip the missed dose and take the next one at your regular time. Do not take a double dose to compensate. Taking two doses at once may cause an excessive drop in blood pressure, leading to dizziness, fainting, or in severe cases, falls and injury. If you frequently forget doses, consider setting a daily alarm or using a pill organizer.

Overdose

An overdose of Copalia may cause excessive vasodilation, leading to marked hypotension and potentially reflex tachycardia. In severe cases, circulatory shock with fatal outcome has been reported. Symptoms of overdose may include severe dizziness, fainting, rapid heartbeat, nausea, and loss of consciousness.

If overdose is suspected, contact your local poison control center or emergency services immediately. Treatment is supportive and symptomatic. For amlodipine overdose, activated charcoal may be effective if administered within 2 hours of ingestion. Cardiovascular support may include intravenous fluids, vasopressors, and intravenous calcium gluconate. Valsartan is unlikely to be removed by hemodialysis due to its high plasma protein binding.

What Are the Side Effects of Copalia?

The most common side effects of Copalia include peripheral edema (swelling of ankles/feet), headache, nasopharyngitis (common cold), dizziness, and fatigue. Serious but rare side effects include severe hypotension, angioedema, and liver function abnormalities. Most side effects are mild and may improve as your body adjusts to the medication.

Like all medications, Copalia can cause side effects, although not everyone experiences them. The side effect profile of Copalia reflects the known adverse effects of both amlodipine and valsartan. Notably, the combination may have a favorable side effect profile compared to amlodipine alone, as valsartan can reduce the peripheral edema commonly caused by amlodipine. This is because amlodipine causes precapillary vasodilation, leading to increased capillary hydrostatic pressure and fluid extravasation, while valsartan causes both precapillary and postcapillary vasodilation, reducing the pressure gradient and counteracting edema formation.

Clinical trials of the amlodipine/valsartan combination, including the EX-EFFeCTS and EX-FAST studies, have demonstrated that the incidence of peripheral edema is significantly lower with the combination compared to amlodipine monotherapy at equivalent doses. This is an important clinical advantage, as peripheral edema is one of the most common reasons patients discontinue amlodipine therapy.

The following side effects have been reported in clinical trials and post-marketing surveillance. If you experience any side effect that is bothersome, persistent, or worsening, contact your healthcare provider. Report any serious adverse events through your national pharmacovigilance reporting system.

It is important to note that the occurrence of peripheral edema with Copalia is generally lower than with amlodipine monotherapy at equivalent doses. In clinical studies, the incidence of edema was approximately 5.4% with the amlodipine/valsartan 5/80 mg combination compared to 8.7% with amlodipine 5 mg alone. This edema-sparing effect is considered a clinically meaningful advantage of the combination therapy.

How Should You Store Copalia?

Store Copalia below 30°C (86°F) in the original packaging to protect from moisture. Keep out of reach and sight of children. Do not use after the expiry date printed on the package.

Proper storage of Copalia is essential to ensure the medication retains its effectiveness throughout its shelf life. The film-coated tablets should be stored at a temperature not exceeding 30°C (86°F). Do not freeze. Keep the tablets in their original blister packaging until the time of use, as the blister foil protects the medication from moisture and light degradation.

Store Copalia in a safe place out of the reach and sight of children. Accidental ingestion by children can cause serious hypotension and requires immediate medical attention. Do not transfer the tablets to another container, as this may lead to confusion about the medication identity and expiry date.

Check the expiry date on the packaging before taking each tablet. Do not use Copalia after the expiry date (month/year) stated on the carton and blister. The expiry date refers to the last day of that month. Expired medication may have reduced potency and should be disposed of properly.

Do not dispose of Copalia via wastewater or household waste. Return unused or expired medication to your local pharmacy for safe disposal through approved pharmaceutical waste programs. This helps protect the environment and prevents accidental exposure.

What Does Copalia Contain?

Each Copalia tablet contains two active substances: amlodipine 5 mg (as amlodipine besylate) and valsartan 80 mg. The tablet also contains inactive excipients necessary for manufacturing, stability, and the film coating.

The active pharmaceutical ingredients in Copalia are:

• Amlodipine besylate — equivalent to 5 mg amlodipine. Amlodipine besylate is the besylate salt form of amlodipine, a dihydropyridine calcium channel blocker. The besylate salt was chosen for its favorable physicochemical properties, including good water solubility and stability.
• Valsartan — 80 mg. Valsartan is a non-peptide, orally active angiotensin II receptor antagonist that selectively blocks the AT1 receptor subtype. Its chemical formula is C₂₄H₂₉N₅O₃ with a molecular weight of 435.52 g/mol.

The inactive ingredients (excipients) in Copalia tablets typically include:

• Tablet core: Microcrystalline cellulose, crospovidone, colloidal anhydrous silica, magnesium stearate
• Film coating: Hypromellose, titanium dioxide (E171), macrogol, talc, iron oxide yellow (E172) — the exact coating composition may vary depending on the tablet strength and manufacturer

Copalia tablets are dark yellow, oval-shaped, film-coated tablets. The specific markings on the tablet may include the dosage strength and a manufacturer code for identification purposes. If you have known allergies to any excipient (particularly titanium dioxide or iron oxide colorants), inform your pharmacist before filling your prescription.